Related Experiment Video
Updated: Apr 23, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening
Published on: August 29, 2015
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas
Sarah J Larkin1, Francesco Ferraù2, Niki Karavitaki2
1Nuffield Department of Clinical NeurosciencesDepartment of Neuropathology, Level 1 West Wing, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UKDepartment of EndocrinologyBarts and London School of Medicine, Queen Mary University of London, London EC1A 6BQ, UKDepartment of EndocrinologyOxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK sarah.larkin@ndcn.ox.ac.uk.
Objective:
The pathogenetic mechanisms of sporadic somatotroph adenomas are not well understood, but derangements of the cAMP pathway have been implicated. Recent studies have identified L206R mutations in the alpha catalytic subunit of protein kinase A (PRKACA) in cortisol-producing adrenocortical adenomas and amplification of the beta catalytic subunit of protein kinase A PRKACB in acromegaly associated with Carney complex. Given that both adrenocortical adenomas and somatotroph adenomas are known to be reliant on the cAMP signalling pathway, we sought to determine the relevance of the L206R mutation in both PRKACA and PRKACB for the pathogenesis of sporadic somatotroph adenomas.
Design:
Somatotroph adenoma specimens, both frozen and formalin-fixed, from patients who underwent surgery for their acromegaly between 1995 and 2012, were used in the study.
Methods:
The DNA sequence at codon 206 of PRKACA and PRKACB was determined by PCR amplification and sequencing. The results were compared with patient characteristics, the mutational status of the GNAS complex locus and the tumour granulation pattern.
Results:
No mutations at codon 206 of PRKACA or PRKACB were found in a total of 92 specimens, comprising both WT and mutant GNAS cases, and densely, sparsely and mixed granulation patterns.
Conclusions:
It is unlikely that mutation at this locus is involved in the pathogenesis of sporadic somatotroph adenoma; however, gene amplification or mutations at other loci or in other components of the cAMP signalling pathway, while unlikely, cannot be ruled out.
Insights
Researchers investigated mutations in protein kinase A (PKA) genes, PRKACA and PRKACB, for sporadic somatotroph adenomas. No L206R mutations were found, suggesting this specific mutation is not involved in the disease.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Sporadic somatotroph adenomas' pathogenesis is unclear, but cAMP pathway dysregulation is suspected.
- L206R mutations in PRKACA are found in adrenocortical adenomas, and PRKACB amplification in Carney complex-associated acromegaly.
Purpose of the Study:
- To investigate the role of L206R mutations in PRKACA and PRKACB in the development of sporadic somatotroph adenomas.
Main Methods:
- Analyzed DNA from 92 sporadic somatotroph adenoma specimens (1995-2012).
- Determined PRKACA and PRKACB DNA sequence at codon 206 using PCR and sequencing.
- Correlated findings with patient data, GNAS mutational status, and tumor granulation patterns.
Main Results:
- No L206R mutations in PRKACA or PRKACB were detected in any of the 92 analyzed specimens.
- Absence of mutation was consistent across wild-type and mutant GNAS cases and different tumor granulation patterns.
Conclusions:
- The L206R mutation in PRKACA and PRKACB is unlikely to be a significant factor in sporadic somatotroph adenoma pathogenesis.
- While less probable, other genetic alterations like gene amplification or mutations in different cAMP pathway components cannot be entirely excluded.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
cAMP-dependent Protein Kinase Pathways
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades

